For Chronic Myeloid Leukemia Patient Group Advocates

In light of the circumstances surrounding the global COVID-19 outbreak, the CML Advocates Network Steering Committee met via video-conference yesterday to decide on the future of our annual CML Horizons conference which was due to take place in San José, Costa Rica from May 1-3.
 
Given the health risks posed to patients as well as the current travel restrictions for which there is no firm indication as to how long they may continue, the Steering Committee has decided to cancel the Costa-Rica CML Horizons conference and to re-schedule the event, circumstances permitting, in Europe in November 2020. 

Even though it has been a difficult decision, the health of conference delegates remains our priority.  We will continue to closely monitor the global situation and incorporate WHO recommendations on safety and travel into our sources of advice.

We will confirm the new dates, venue and further details about the conference in the coming days.

We would also like to express our sincere gratitude to all CML patient advocates, doctors, service providers and volunteers who have helped us with the organisation and program planning for Horizons 2020 Costa Rica. 
 
Our commitment now is to work hard to reschedule and prepare an excellent CML Horizons conference for which we intend to exceed the expectations of conference attendees as they continue to learn, share and grow all together.
 
Stay tuned and follow our social media channels for more information!

The CML Advocates Network is closely monitoring the situation of CML patients worldwide in collaboration with the International Chronic Myeloid Leukemia Foundation (iCMLf) and their network of CML experts.

If you know of any Chronic Myeloid Leukemia patient(s) who have been diagnosed via testing with COVID-19, let us know by completing this form.

Your personal data are processed for healthcare and research reasons and never for marketing purposes.
 

The CML Community Advisory Board (CAB) is in the process of planning the network's CAB meetings in 2020. 

Please take a moment to complete our short survey to inform the CML Advocates Network view on the access situation to Ponatinib and to mutation testing in your country or region in an effort to enable us to have a strategic dialogue about access to this treatment in the context our CAB.

We would kindly request you to complete the survey before Wednesday, March 25th.